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ABSTRACT 
 
Role of CTCF in HOX genes regulation and breast cancer tumorigenesis 
 
Muhammad Mustafa 
 
Department of Medical Science 
The Graduate School, Yonsei University 
 
(Directed by Professor Myoung Hee Kim) 
 
  CTCF (or CCCTC-binding factor), a ubiquitous 11-zinc finger multifunctional 
protein has distinct molecular functions such as transcriptional activation, 
transcriptional repression, or enhancer blocking activity, in a locus-specific manner. 
Identification of somatic mutations in CTCF in different cancers and its involvement 
in cellular growth, differentiation and apoptosis point towards its role in cancer 
progression. HOX genes not only play important roles in defining body patterning 
during embryonic development, but also control numerous cellular events in adult 
cells. Deregulated HOX gene expression in different cancers including breast cancer is 
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now increasingly being reported. 
 In this work we wanted to investigate that how CTCF contribute in the breast cancer 
cell survival directly and through modulation of HOX genes. We performed CTCF 
gain and loss of function studies to see its effects on HOX genes expression and 
cancer cell survival and identified several directly regulated HOX genes including 
HOXA4, HOXC8 and HOXA10. Among HOX, HOXA10 is an emerging tumor 
suppressor for its role in activation of p53 and in countering tumorigenesis in breast 
cancer. HOXA10 silencing is associated with different cancers but the underlying 
mechanism is still elusive. Our data defines the putative promoter region of HOXA10 
5.3-6.1 kb upstream of its start codon and its negative regulation by CTCF. Analysis 
of histone modification reveals that the presence of CTCF is associated with 
decreased active histone marks H3K4me3 and increased repressive histone marks 
H3K27me3 on HOXA10 locus. Together with in silico analysis and specially designed 
in-vitro mutation assay we identified an important promoter element, flanked with 
CTCF core motif in HOXA10 promoter region. Based on the evidence in our study, 
we propose that CTCF binding site co-exist within core promoter region of HOXA10 
and CTCF presence not only maintains the inactive state of local chromatin but also 
interfere with the transcription machinery and induce transcriptional silencing of 
HOXA10. Epigenetic silencing of HOXA10 by CTCF in breast cancer cells may 
contribute towards tumorigenesis by avoiding cell cycle arrest, decreasing apoptosis 
and promoting metastasis. 
3 
 
 We observed depletion of CTCF leads to decreased cell growth and proliferation in 
breast cancer cell line MCF-7 than normal breast epithelial cell line MCF10A. We 
found that it happens due to the direct and indirect activation of p53 signaling cascade 
in CTCF knock down breast cancer cells. CTCF binding near the promoter region of 
TP53 is marked with increased H3K27me3 and decreased H3K4me3. p53 activation 
by CTCF knock down resulted in cell cycle arrest at G1/S check point and enhanced 
apoptosis due to the activation of p21 and Bax respectively. Nuclear localization of 
p53 is related with CTCF depletion in MCF-7 cells and it is consistent with our 
observation that p53 cascade is activated in the absence of CTCF. CTCF also induce 
transcriptional silencing of HOXA10 which is known to activate p53.We observed 
that HOXA10 co-localize with p53 in breast cancer cells and depletion of nuclear 
HOXA10 results in decreased nuclear p53. Several key components of autophagy 
signaling pathway e.g., ATG13, SQSTM1 (P62) and LC3-II as well as lysosome 
number are positively related to CTCF levels in MCF-7 cells.  
  Taken together we demonstrated that CTCF induce transcriptional silencing of p53 
directly as well as through HOXA10 to contribute in the breast cancer survival and 
tumorigenesis. 
 
------------------------------------------------------------------------------------------------------- 
Key words : breast cancer, CTCF, HOXA10, p53 
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I.INTRODUCTION 
 
CCCTC binding factor (CTCF) is a highly conserved and ubiquitous transcription 
factor known to be involved in various unrelated cellular functions.
1, 2
 The 82 kDa 
protein has three distinct domains: N-terminal, C-terminal and a central DNA binding 
11-zinc finger domain.
3
 CTCF uses different combinations of its 11-Zn-fingers in 
DNA binding domain to form different complexes for its multifunctional role in 
regulation of gene expression.
2
 Its main functions are transcriptional activation, 
repression, and enhancer blocking depending on the genetic locus involved.
4-6
 Many 
of the functions of CTCF involved long-range genome processes such as chromatin 
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looping, chromatin insulation and nuclear organization.
7-9
 These are regulated by 
interactions with other protein partners and post translational modifications.
10
  
Originally discovered as a transcriptional repressor of chicken c-myc gene,
11
 CTCF is 
also known to inhibit hTERT and Bax gene transcription by binding near to their 
promoter regions.
12, 13
 
 
 
Figure 1.  CTCF function in chromatin biology.
14
 (a) Functional categories of CTCF 
binding sites across the genome (b) (i) CTCF binding sites are found at boundaries 
that separate active and inactive domains. CTCF binding to (ii) enhancer-like 
sequences and (iv) gene promoters can facilitate looping between these sequences. (iii) 
CTCF binding in between enhancers and gene promoters can block the interaction 
between an enhancer and its target promoter. 
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 CTCF mutation is found in many cancers including breast cancer.
15
 It regulates many 
cancer related genes involved in cellular growth, proliferation, differentiation and 
apoptosis.
16-20
 Higher levels of CTCF was found in breast tumors and in breast cancer 
cell lines as compared to the normal cells and is associated with resistance towards 
apoptosis.
21
 CTCF counteract the influence of positive regulators on Bax promoter 
and its depletion activates Bax transcription and promotes apoptosis in breast cancer 
cell lines.
13
 The growing evidences over the years support the idea that higher levels 
of CTCF in breast cancer cells contribute in cancer cell survival by transcriptional 
repression of one or many important tumor suppressor genes like Bax. Therefore it is 
important to investigate the role of CTCF in regulation of cancer related genes to 
unveil the effect on breast cancer tumorigenesis. 
HOX constitute a family of transcription factors that play key roles in embryonic 
development. They are characterized by a highly conserved homeodomain region 
consisting of a 60-amino acid motif which enables HOX proteins to bind to specific 
regions of DNA in order to transcriptionally activate or repress target genes.
22
 In 
mammals, the 39 HOX genes organized into 4 paralogous groups (A, B, C and D) 
located on 4 different chromosomes.
23
 During development, HOX gene expression is 
regulated spatially and temporally, followed by a strict code to influence patterning of 
the anterior to posterior axis. In adults, the expression pattern of HOX genes were 
conserved and maintained in a tissue specific manner
24
 and gave unique 
morphological identities to the cells.
25, 26
 
7 
 
 
Figure 2. Genomic organization of human HOX genes and their collinear expression 
during development.
27
 
 
 HOX proteins regulate several key cellular functions such as cell adhesion, migration 
and cell cycle to maintain cellular homeostasis,
22
 however, many HOX genes are 
found to be deregulated in different cancers and some of them have already 
established their roles in breast cancer tumorigenesis and progression.
28-35
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Figure 3. Downstream targets of HOX proteins. HOX downstream targets are 
involved in numerous cellular processes including organogenesis, cellular 
differentiation, cell adhesion and migration, cell cycle and apoptosis. Several 
downstream targets play multiple roles in several pathways, with many acting as 
transcription factors and regulating their own subset of genes.
36
 
 
   Many HOX genes including an emerging tumor suppressor HOXA10 is silenced in 
patients with hereditary breast cancer.
37
 During development, HOXA10 controls 
uterine organogenesis and also functions for endometrial differentiation in adult.
38
 In 
endometrial carcinoma, downregulation of HOXA10 by promoter methylation is 
associated with increased tumor grade.
39
 In differentiating myelomonocytic cells 
9 
 
(U937), HOXA10 binds to the promoter region of p21 and activate its transcription 
which results in cell cycle arrest and differentiation.
40
 HOXA10 is also known to 
regulate p53 in breast cancer cells
34
 and its down-regulation increases cell migration 
and metastasis.
26
 These studies strengthen the role of HOXA10 as a tumor suppressor 
in breast cancer cells and propose its activation as a potential treatment but the 
molecular mechanism of how HOXA10 is regulated in breast cancer cells is still 
elusive. 
Human HOX gene clusters contain several CTCF binding sites which establish 
discrete functional chromatin domains. Deletion of CTCF binding site(s) within HOX 
cluster results in expansion of active chromatin into the repressive domains.
41
 CTCF 
functions as a controller of HOXA cluster silencing and mediate PRC2-repressive 
higher-order chromatin structure.
42
 The ability of CTCF to modulate HOX expression 
pattern will subsequently affects the downstream signaling cascades and contributes 
in cancer development. 
The higher level of CTCF in breast cancer cell lines and the availability of huge 
number of CTCF binding sites in human genome
43
 indicate that it might involve in the 
silencing of several other tumor suppressor gene on a global scale. We investigate the 
role of CTCF in breast cancer cell progression directly or by modulating HOX gene 
expression. By using ER/PR positive (MCF-7, BT-474 and T-47D) breast cancer cell 
lines and normal breast epithelial cell line (MCF10A) we demonstrate that CTCF 
depletion affects breast cancer proliferation by a combinatorial effect of cell cycle 
10 
 
arrest, increased apoptosis and blocking autophagy. CTCF also suppress the 
transcription of several important HOX tumor suppressors like HOXA4, HOXA10 and 
HOXC8 and contribute in breast cancer tumorigenesis. Targeted deletions of CTCF 
binding sites to reduce CTCF enrichment near the promoter region of tumor 
suppressor genes like HOXA10 will activate cellular defense mechanism and can 
induce apoptosis. The normal breast cells which are not much dependent on CTCF 
might be spared and can survive with this type of targeted therapy 
 
 
Figure 4. p53 signaling cascade. p53 signaling pathway can be activated on DNA 
11 
 
damage and other types of stress as well as by HOXA10. Activation of p53 results in 
cell cycle arrest and apoptosis by upregulation of p21 (CDKN1A) and Bax 
respectively. 
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II. Materials and Methods 
 
 1. Cell Lines and Cell Culture 
   MCF-7, BT-474 and T-47D cells were kindly provided by Drs. Young Nym Kim 
and Kyung Tae Kim (National Cancer Center Korea). All the breast cancer cell lines 
were maintained at 37
о
C in an atmosphere of 5% CO2 using following conditions. 
MCF-7, BT-474 were cultured in Dulbecco’s modified Eagle’s medium (DMEM; 
WelGENE Inc, Daegu Korea) and T-47D cells were cultured in RPMI 1640 
(WelGENE Inc). The media were supplemented with 10% fetal bovine serum (FBS; 
WelGENE Inc) and 1X antibiotic antimycotic solution (WelGENE Inc). 
 
 2. RNA Isolation and RT-PCR 
   Total RNA from the cultured cells was isolated using Trizol reagent (Invitrogen 
Carlsbad, CA USA) according to the manufacturer’s instruction. 500 ng of total RNA 
was reverse transcribed (RT) using ImProm-II
TM
 Reverse Transcriptase (Promega, 
Madison, WI, USA). PCR was performed in replicates using G Taq polymerase 
(Cosmogenetech, Seoul Korea). Following PCR conditions were used for 
amplification: initial denaturation for 3 min at 95
о
C followed by 25-35 cycles ( 25 
cycles for β-Actin, 32 cycles for CTCF and 35 cycles for HOXA genes) of 95оC for 
30 sec 58-60
о
C (58
о
C for β-Actin, 60оC for CTCF and HOXA genes) for 30 sec, 72оC 
for 30 sec. Final elongation was done at 72
о
C for 5 min. PCR primers for HOX genes 
13 
 
were previously reported.
44
 Primers for other genes were listed in Table 3. For 
quantification, ImageJ software was used. Minimum three independent biological 
replicates were analyzed and Student’s t-test was used to calculate p-value wherever 
required. 
 
 3. Overexpression of CTCF 
   Full length CTCF cDNA was cloned into pCDNA3 vector to obtain pCTCF 
recombinant plasmid. Human breast cancer cell lines were transfected with either 
pCDNA3 control or pCTCF plasmid DNA using Lipofectamin 2000
TM
 (Invitrogen) or 
Attractene (QIAGEN) according to the manufacturer’s protocol. Transient 
overexpression of CTCF was confirmed after 72 hr at mRNA level by RT-PCR and at 
protein level by western blot analysis using CTCF antibody ( Cell signaling, 3418). 
 
 4. Knockdown of CTCF 
   shRNA oligos (Table 1) targeting two different positions on CTCF mRNA 
(shCTCF1, gcggaaagtgaacccatgata and shCTCF2, cctcctgaggaatcaccttaa) were 
designed and synthesized by Cosmo GENETECH. Oligos were annealed to generate 
shRNA inserts with AgeI and EcoRI sites, and cloned into pLKO.1 puro to generate 
pLKO.1-shCTCF1 and pLKO.1-shCTCF2. Packaging plasmid (pCMV-dR8.91) and 
envelop plasmid (pVSV-G) were co-transfected with control (pLKO.1) or Non-
specific shRNA containing vector (pLKO1-NS) or shCTCF containing vector 
14 
 
(pLKO1-shCTCF1 or pLKO1-shCTCF2) using Lipofectamin 2000
TM 
(Invitrogen) in 
HEK-293T cells.  Lentiviruses from the media were harvested twice after 48 hr and 
72 hr, pooled, filtered (Minisart 
®
 0.45 µM CE) and saved at -20
 о
C. For CTCF knock 
down, breast cancer cells were grown in media containing lentivirus particles (1-10 
dilution) for 72 hr in the presence of 8 µg/mL polybrene (Sigma). Selection was done 
using 1.5µg/mL puromycine for 48 hr and CTCF knockdown was confirmed by RT-
PCR. 
 
 5. Dual Luciferase Assay  
   Different genomic DNA fragments (Table 2) from HOXA10 locus were amplified 
using pfu polymerase (Solgent) and cloned into pGL3-basic vector (Promega) using 
KpnI and HindIII sites. Restriction enzyme sites were incorporated via forward and 
reverse primers (Table 2). HEK-293T and MCF-7 cells were co-transfected with 
Renilla luciferase vector (pRL Renilla luciferase control) and either of control pGL3-
basic vector or individual luciferase genomic construct using Attractene (QIAGEN) 
according to the manufacturer’s protocol. Promoter activity of individual construct 
was measured using Dual luciferase® assay system (Promega) after 72 hr of 
transfection and normalized using Renilla luciferase signal. To analyze the effect of 
CTCF on the promoter activity, MCF-7 cells were co-transfected with Renilla 
luciferase vector and pGL3-A10-2 vector with either pCDNA3 or pCTCF vector and 
promoter activities were measured as previously described. Minimum 4 independent 
15 
 
biological replicates were examined to obtain reliable results.  
 
 6. In-vitro mutation assay (IMA) 
   Wild type pGL3-A10-2 plasmid was mutated using PCR based introduction of 
mutation(s) to generate pGL3-A10-2-m1, pGL3-A10-2-m2 and pGL3-A10-2-m3 
plasmids. Primers with mutated sequences F2 and R2 were used to amplify DNA 
fragments with their corresponding F1 and R1 primers according to the scheme in 
Figure 14 (Figure 14A). Resulting DNA sub fragment were purified and 1 μl of 
equimolar mixture of sub-fragments were used as a template for assembly PCR with 
F1 and R1 primers to generate mutated A10-2 fragment (Figure 14B). A10-2-mutated 
fragments are later cloned back into pGL3-basic vector for Dual luciferase assay 
(Figure 14C).   
 
 7. Chromatin Immunoprecipitation (ChIP) Analysis 
   Chromatin for ChIP experiment was prepared from MCF-7, BT-474 and T-47D 
cells by fixing the cells in 37 % formaldehyde for 15 min, followed by quenching 
with 2.5 M Glycine for 10 min. Sonication of cross linked genomic DNA was done 
using Sonics Vibra Cell
TM
 to get 500~1000bp DNA fragments (Figure 13A) with 
condition 1 (Time: 7 min, Pulse: 10 sec Interval 10 sec). In case of modified ChIP 
experiment  (Figure 13B) DNA fragment up to 250bp were generated using 
Condition 2 and 3 (Time: 9 min and 11 min, respectively, for condition 2 and 3 with 
16 
 
same pulse and interval as condition 1). ChIP was performed using antibodies against 
CTCF, H3K4me3 (abcam, 1012), H3K27me3 (abcam, 6002) and IgG (Santa Cruz 
Biotechnology, sc 2027). Immune precipitated DNA was extracted using 
Cosmogenetech Labopass
TM
 PCR purification kit. Two μl of eluted DNA was used as 
a template to perform PCR, DNA was resolved on 1.5% agarose and quantified using 
ImageJ software. The primers corresponding to CBS1 and CBS2 sites (Figure 12) are 
given in Table 3. Minimum three or more independent biological replicates were used 
for quantitation. 
 
 8. Immunocytochemistry 
   MCF-7, BT474 and T-47D were fixed using 4% paraformaldehyde (PFA) for 15 
min, rinse with cold Phosphate buffer saline PBS twice and permeabilized with 0.25% 
Triton-X100 in PBS for 10 min. The cells were washed with PBS 3 times for 5 min. 
Blocking was done using 1% BSA in Phosphate buffer saline with 0.1% Tween PBST 
for 30 min. In case of HOXA10 and CTCF, cells were washed with PBS 3 times for 5 
min. Cells were incubated overnight at 4
о
C in a humidified chamber with primary 
antibody (HOXA10 N-20: Sc-17158 Goat polyclonal and/or CTCF Rabbit 
monoclonal antibody ( Cell signaling, 3418 ) diluted in blocking buffer at 1:50. After 
washing with PBS three times for 5 min, cells were incubated with secondary 
antibody (Donkey Anti-Goat IgG Alexa Flour
®
 488, ab150129 and/or  Goat Anti-
Rabbit IgG Alexa Flour 594 (ab150084)) in blocking buffer for 1 hr in dark. In case of 
17 
 
p53 and CTCF, primary antibodies p53 (DO-1) sc-126 and CTCF Rabbit monoclonal 
antibody ( Cell signaling, 3418 )  were detected by secondary antibodies Goat Anti-
Mouse IgG Alexa Flour 488 (ab150117) and  Goat Anti-Rabbit IgG Alexa Flour 594 
(ab150084). In case of p53 and HOXA10, primary antibodies p53 (DO-1) sc-126 and 
HOXA10 N-20: Sc-17158 Goat polyclonal were detected by secondary antibodies 
Goat Anti-Mouse IgG Alexa Flour 488 (ab150117) and Rabbit Anti-Goat IgG Alexa 
Flour 568 (ab175707). Counter stain with 0.5 µg/ml DAPI (invitrogen
TM
) for 10 min 
and analyzed using Zeiss LSM700 Confocal microscope.  
 
 9. MTT Assay 
  5000 cells per well in 96-well plate were 24 hr before treatment with  3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). 20 µl of 5mg/mL 
MTT (in PBS) was added to each well, incubated for 3.5 hr at 37°C. Removed media 
and added 150 µl of MTT solvent (4mM HCL, 0.1% Nondet P-40 (NP-40) in Iso-
propanol). Kept on shaker for 15 min and read at absorbance at 570 nm in Elisa Plate 
Reader. 
 
 10. Cell Cycle Analysis 
    3.0 x 10
5
 cells were harvested and fixed using 2ml of 70% Ethanol, kept at 4°C 
for 2.30 hr. Ethanol was removed and cells were washed twice with PBS and re-
suspended in 475 µl of PBS. Cells were passed through syringe to avoid aggregation, 
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5 ul RNAse A (10mg/ml) and 25 µl of PI (1mg/ml) were added. Incubated the cells at 
37°C in dark for 45 min and analyzed using Fluorescence Activated Cell Sorter 
(FACS). 
 
 11. Apoptosis Analysis 
    EzWay Annexin V-FITC Apoptosis Detection Kit (KOMABIOTECH) was uded 
to detect apoptosis. 5 x 
105
 cells were transferred in microtube, centrifuged, washed 
with 0.5mL cold PBS twice and with 0.5mL cold Binding buffer. Added 1.25 µl (200 
µg/ml) of Annexin V-FITC and incubated at room temperature for 15 min in dark. 
Removed the supernatant and washed cells with 0.5mL cold Binding buffer. Added 10 
µl of PI (30 µg/ml) to the cells suspension and analyzed by FACS.  
 
 12. Autophagy detection by Lysotracker  
    Lysotracker DND-26 (Cell signaling 8783) were diluted 1:10,000 directly into 
cell culture media to make 100 nM final concentration. Live cells were analyzed 
using fluorescent microscopy immediately after treatment without fixation. 
 
13. PCR array 
    RNA samples from CTCF knock down and control MCF-7 cells were used 
for Human Breast Cancer RT² Profiler™ PCR Array system by SABiosciences.  
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 14. Statistical analysis 
    For all the experiments, minimum three independent biological replicates 
were analyzed for quantitation. Data are presented as mean ± standard error. 
Student’s t-test was used. 
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III. RESULTS 
 
 1. CTCF regulate expression of HOX genes in MCF-7 
    CTCF ChIP-Seq in MCF-7 cells
45
 adopted from Encode genome browser showed 
that several CTCF binding sites were present in HOX cluster (Figure 5). This 
indicates a possible role of CTCF in regulation and maintenance of HOX cluster 
expression pattern in MCF-7.  
 
 
Figure 5, CTCF binding sites within HOX genes cluster
45
 in MCF-7 cells adopted 
from Encode genome browser. 
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In order to find a strong candidate gene regulated by CTCF among HOX, we first 
performed gain and loss of function study and examined the effect of CTCF on the 
expression of HOX cluster genes (Figure 6-8). The overexpression of CTCF in MCF-
7 was validated at mRNA level by RT-PCR (6A) and at protein level by western 
blotting (Figure 6B).  Expression of HOX genes were analyzed using semi-
quantitative RT-PCR (Figure 6C-8A). HOXA5 was upregulated while HOXA4, 
HOXA10 and HOXC8 were downregulated in CTCF over-expressing MCF-7 cells 
(Figure 6C), Others were unchanged. When CTCF was knocked down using 
lentivirus (Figure 7A,B) and expression pattern of HOX genes were analyzed, it was 
found that HOXA4, HOXA10 and HOXC8 were upregulated (Figure 7C). Semi-
quantitative PCR analysis confirmed that expression of HOXA4, HOXA10 and 
HOXC8 were inversely related to CTCF levels in MCF-7 cells (Figure 8B).  
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Figure 6. Effect of CTCF overexpression on the expression pattern of HOX genes in 
MCF-7 cells. (A) mRNA levels of CTCF in control (pCDNA3) and CTCF over 
expressing (pCTCF) MCF-7 cells (B) Western blot analysis of control and CTCF 
overexpressing MCF-7 cells. (C) A representative data showing up or down regulation 
of HOX genes in CTCF overexpressing cells. 
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Figure 7. Effect of CTCF knock down on the expression pattern of HOX genes in 
MCF-7 cells. (A) Representation of pLKO.1-puro vector used to generate shRNA 
against CTCF mRNA  (B) ) mRNA levels of CTCF in control non-specific (NS) and 
CTCF knock down (KD) MCF-7 cells (C) A representative data showing up or down 
regulation of HOX genes in CTCF knock down MCF-7 cells.  
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Figure 8. Semi-quantitative RT-PCR data of candidate HOX genes in CTCF over 
expressing and knock down MCF-7 cells. (A) Result of semi-quantitative RT-PCR 
showing the change in expression pattern of selected genes in CTCF overexpressing 
cells. Error bars are standard error, n = 4. *p<0.01. (B) RT-PCR analysis of candidate 
gene in CTCF knockdown cells. Error bars are standard error, n = 4. *p<0.05 
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Table 1. Synthetic shRNA oligos for CTCF knock down 
Oligo Sequence 
shCTCF1-F 5’CCGGGCGGAAAGTGAACCCATGATACTCGAGTATCATGGGTTCACTTTCCGCTTTTTG 
shCTCF1-R 5’AATTCAAAAAGCGGAAAGTGAACCCATGATACTCGAGTATCATGGGTTCACTTTCCGC 
shCTCF2-F 5’CCGGCCTCCTGAGGAATCACCTTAACTCGAGTTAAGGTGATTCCTCAGGAGGTTTTTG 
shCTCF2-R 5’AATTCAAAAACCTCCTGAGGAATCACCTTAACTCGAGTTAAGGTGATTCCTCAGGAGG 
 
Among three candidate HOX genes, HOXA10, in particular, has been proposed as a 
tumor suppressor gene but not well studied for its regulation mechanism, we therefore 
selected HOXA10 as a candidate gene to explore further for its regulation by CTCF. 
ICC data proved that HOXA10 nuclear and cytoplasmic expression was also 
increased after CTCF knockdown in MCF-7 cells (Figure 9). 
 
Figure 9. Immunocytochemistry (ICC) data showing HOXA10 localization in control 
26 
 
non-specific (NS) and CTCF knockdown (KD) MCF-7 cells. 
 
 2. Identification of promoter region of HOXA10 and effect of CTCF    
on promoter activity      
To investigate whether CTCF regulates HOXA10 expression directly by binding 
to its promoter region, we first performed a promoter assay using different gnomic 
DNA fragments from region 1 (A10-2; -268 to +507) and region 2 (A10-3; +4589 to 
+5861) of HOXA10 locus (Figure 10A and Table 2). To our surprise, no promoter 
activity was observed from region 2 of HOXA10 locus, which appears to be a typical 
regulatory region in most of the protein coding genes. Instead we found a significant 
promoter activity with A10-2 DNA fragment from region 1 (Figure 10B). Serial 
deletion of A10-2 fragment proved that entire promoter activity can be detected only 
with the full length of A10-2 fragment as deletion from both ends caused significant 
loss of promoter activity (Figure 10B). Similar results were obtained when the 
constructs were transformed in HEK-293T cells (Figure 10C). 
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Figure 10. Identification of promoter region of HOXA10. (A) Representation of 
HOXA10 locus (Figures not drawn to scale) showing all three exons with CTCF 
binding sites on exon 1 and exon 3. Start and stop codons are marked with red bar and 
asterisk, respectively. Genomic positions of DNA fragments of HOXA10 region 1 and 
region 2 (red and blue boxes, respectively) for dual luciferase promoter assay are 
represented with their deletion constructs. (B) Promoter activities of individual 
constructs by dual luciferase reporter assay. Error bars are standard error, n=4. (C) 
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Relative luciferase reporter activities of different genomic DNA constructs in pGL3-
basic vector normalized with Renilla luciferase vector (pRL-TK) in HEK-293 cells. 
n=3 and error bars are SE 
 
Table 2. Primers for the amplification of  genomic constructs for luciferase assay. 
Genomic constructs with their product sizes and genomic positions as represented in 
Figure 10A, KpnI and HindIII sites are in bold 
 
 
 
 When CTCF is overexpressed in MCF-7 cells (Figure 11A), the promoter activity 
of A10-2 fragment was decreased (Figure 11B). The negative effect of CTCF on the 
promoter activity of A10-2 fragment was observed in a dose-dependent manner 
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(Figure 11C). Taken together, we concluded that the promoter activity for HOXA10 
transcription lies 5.3 to 6.1 kb upstream of the start codon of HOXA10 
(chr7:27,219,252-27,220,026) and is negatively regulated by CTCF. 
 
 
 
Figure 11. Effect of CTCF on HOXA10 promoter activity. (A) mRNA expression 
level of CTCF in MCF-7 cells expressing empty vector or CTCF expressing vector 
with pGL3-A10-2. (B) Relative promoter activities of A10-2 fragment in control 
pCDNA3 set as 100 and CTCF expression vector. Error bars are standard error, n=4, 
*p < 0.01. (C) CTCF dose response on the promoter activity of A10-2 DNA fragment 
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with varying amounts (0-200 ng) of pCDNA3 control and pCTCF expression vectors.  
 
 3. CTCF binding to HOXA10 promoter region maintains inactive local    
  chromatin state 
    According to the ChIP-Seq data
45
 uploaded in ENCODE genome browser (Figure 
5), HOXA10 locus contains two CTCF binding sites (CBS) i.e., CBS1 and CBS2, 
found in exon 1 and exon 3, respectively. Each of the two CTCF binding sites was 
confirmed by ChIP-PCR with two sets of primers A and B spanning approximately 
200 bp (Figure 12A, Table 3). Interestingly, we found that CTCF binds preferentially 
to CBS1-A site which contains the promoter activity (Figure 12B). Our finding of 
coexistence of putative regulatory region of HOXA10 with the CTCF binding site 
CBS1 strongly suggests a possibility of direct role of CTCF in HOXA10 promoter 
activity. To confirm whether the CTCF affect the promoter activity, we investigated 
the enrichment status of active and repressive histone markers (H3K4me3 and 
H3K27me3) at CBS1. CBS2, which is present within the exon 3, was also included to 
observe the effect of CTCF on the gene body. ChIP analysis for histone modification 
patterns revealed that the promoter region of HOXA10 bound by CTCF is marked 
with higher H3K27me3 not only on the promoter region (CBS1-A) but also in the 
gene body (CBS2-A). Depletion of CTCF on HOXA10 promoter region is associated 
with decreased H3K27me3 and slight increase of H3K4me3 (Figure 12C, D). These 
results suggest that CTCF binding to the promoter region of HOXA10 confers 
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transcriptional silencing by maintaining inactive local chromatin state with higher 
enrichment of repressive histone marks H3K27me3. 
   
 
 
Figure 12. CTCF presence on HOXA10 promoter is associated with repressive 
histone marks. (A) HOXA10 gene locus with two CTCF binding sites (B) ChIP-PCR 
analysis of CTCF binding at site A and site B within CBS1 and CBS2 sites. (C) ChIP-
PCR using control non-specific (Control-NS) and CTCF knockdown (CTCF-KD) 
MCF-7 cells to analyze histone modification on CTCF binding regions. (D) 
Quantitation of PCR results showing the effect of CTCF depletion on the enrichment 
of H3K4me3 and H3K27me3 at the site CBS1-A. 
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Table 3. RT-PCR primers for CTCF and Primers for ChIP analysis (Figure 12) and 
their corresponding genomic locations 
 
Fragment Forward primer Genomic location 
Reverse primer 
   
 
CTCF  
5’ -TGCGAA AGCAGCATTCCTAT-3’  chr16:67,596,310-67,673,088  
5’ -TAGCGCTTG AAGTGCATG-3’  
   
 
CBS1-A  
5’ -AACTCCGGCCCAACCTAG-3’  chr7:27,219,360-27,219,565  
5’ -CATACCAATCACTTCTTGAGGGT-3’  
   
 
CBS1-B  
5’ -AATGCGCCGCTATAAACCC-3’  chr7:27,219,501-27,219,712  
5’ -GGCTTTGACATTGATCGGAAG-3’  
   
 
CBS-2A  
5’ -GAATCGAGAAAACCGGATCC-3’  chr7:27,211,354-27,211,569  
5’ -TCAGAACAAACCAGCCCT-3’  
   
 
CBS-2B  
5’ -AAGCACCAGACACTGGAG-3’  chr7:27,211,528-27,211,718  
5’ -TTAAAGTTGGCTGTGAGCTC-3’  
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 4. Exploration of CTCF binding motif flanked with important promoter   
   element of HOXA10 
    Our ChIP-PCR data confirmed the presence of CTCF binding within the region 
for promoter activity. Using CTCFBSDB 2.0, an online tool, we identified the core 
CTCF binding motif within putative promoter region A10-2 (Figure 15A). The 
identified motif has significant similarity with already established sequences of CTCF 
core motif (Figure 15B). The binding of CTCF on the exact motif was validated using 
modified ChIP experimental scheme with DNA fragments sonicated up to 250 bp 
approximately (Figure 13).  
 
 
Figure 13. Sonicated DNA fragments for ChIP and modified ChIP experiment using 
MCF-7 cells. (A) Sonicated fragments ranged 500-1,000 bp with typical protocol of 
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ChIP method. (B) Extensive sonication reduced chromatin fragments to an average 
size of 250 bp (detailed protocols are in materials and methods).  
 
PCR product was observed from the primers P1/P2 with predicted CTCF binding 
motif, but not with P3/P4, adjacent region without CTCF core motif (Figure 15C). We 
next asked whether this CTCF core motif is overlapped with important promoter 
regulatory region. To get the answer, we generated three mutated A10-2 fragments 
with mutations in CTCF core binding motif (A10-2-m1, m2, and m3; Figure 15D, 
Table 4) using the scheme  (Figure 14) and measured the changes in promoter 
activity.  
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Figure 14. Scheme for the generation of pGL3-A10-2 mutated plasmids for IMA. (A) 
Primers with mutated sequences (red) flanking core CTCF binding motif (blue box) 
were used to generate mutated DNA fragments. K and H represent KpnI and HindIII 
enzyme sites. (B) PCR products resolved on 1.5% agarose gel showing, marker (Lane 
1), 514 bp F1/R2 (Lane 2) and 299 bp F2/R1 (Lane 3) products, along with purified 
assembly PCR product of mutated A10-2 (Lane 4). (C) Cloning of assembly PCR 
product using enzyme sites KpnI and HindIII to produce pGL3-A10-2 mutated DNA 
plasmids for dual luciferase assay. 
 
Dual luciferase reporter assay with wild type A10-2 fragment showed that promoter 
activity was not affected with fragment A10-2-m1 which contains only one nucleotide 
mutation. However, a fragment A10-2-m2 harboring 2 nucleotides changes, as well as 
a fragment A10-2-m3 with many changes within 20 bp CTCF core motif, showed 
significant reduction in promoter activity (Figure 15E). An online tool named “Neural 
network promoter prediction” predicted TATA box at -24 and the transcription start 
site in A10-2 region, as indicated by arrow in Figure 15A. Taken together, we 
concluded that CTCF core binding motif resides 218 bp downstream of transcription 
start site (TSS) flanked with important promoter element of HOXA10. These results 
suggest that the presence of CTCF on the promoter region possibly interferes with the 
transcriptional machinery and thus contribute to induce transcriptional silencing of 
HOXA10 in MCF-7. 
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Figure 15. HOXA10 promoter analysis for CTCF core motif and promoter elements. 
(A) A10-2 DNA fragment sequence with predicted CTCF core binding motif and 
primer sites for ChIP analysis (P1 to P4). TATA box is indicated in red and 
transcription start site is shown as bold with arrow. (B) DNA consensus sequences for 
CTCF core motif shown in.
46
 (C) ChIP-PCR analysis of HOXA10 promoter region 
with modified ChIP protocol. Primer sets P1/P2 and P3/P4 were used. (D) DNA 
sequences of the A10-2 fragments with wild type and three different constructs with 
mutated CTCF core motifs generated for in vitro mutation assay. (E) Relative 
promoter activities of wild type and mutated A10-2 fragments using dual luciferase 
assay. 
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Table 4. Primers to generate A10-2-m1, A10-2-m2 and A10-2-m3 mutated plasmids 
according to the Figure 14 
 
Primer Sequence 
F1  5’-AGAGGTACCAGGGTAGTGGGACAGATCT-3’  
R1  5’-AGAAAGCTTTGTGGCCTCTTACCTTGAC-3’  
F2 Primer for mut1  5’-GCCGCTACGAGATGGCGCACTT-3’  
F2Primer for mut2  5’-TACGAGATAGCGCACTTCCGAT-3’  
F2Primer for mut3  5’-ATTATTATAAAATAATATACTTCCGATCAATGTC-3’  
R2Primer for mut1  5’-AAGTGCGCCATCTCGTAGCGGC-3’  
R2Primer for mut2   5’-AAGTGCGCTATCTCGTAGCGGCT-3’  
R2Primer for mut3  5’-TATATTATTTTATAATAATTGCGCGCCTAGGTTG-3’  
 
 
5. Validation of HOXA10 regulation by CTCF in other breast cancer cell 
lines 
     In order to confirm that presence of CTCF in the promoter region of HOXA10 
induces HOXA10 silencing, we chose two ER-positive breast cancer cell lines, BT-
474 and T-47D. In these two cell lines, CTCF expression levels were similar at both 
mRNA (Figure 16A) and protein levels,
21
 whereas HOXA10 was differentially 
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expressed, i.e., BT-474 showed higher expression of HOXA10 than T-47D (Figure 
16A), which is consistent with the previous report.
44
 HOXA10 in BT-474 found to be 
localized in cytoplasm as well as in nucleus while in T-47D cells no nuclear 
localization of HOXA10 was observed (Figure 16B).  
 
 
 
Figure 16. Differential action of CTCF on HOXA10 expression in breast cancer cell 
lines. (A) mRNA levels of CTCF and HOXA10 in BT-474 and T-47D cells. (B) 
HOXA10 localization in T-47D and BT-474 cells. a-c and d-f show HOXA10, DAPI 
and overlay images in BT-474 and T-47D, respectively. g-i and j-l are the zoom 
images for the area highlighted by square in figure a and d, respectively. 
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We deduced that this effect might be caused by differential CTCF binding on 
HOXA10 promoter region. ChIP-PCR analysis showed that CTCF binds preferentially 
on the promoter region of HOXA10 in T-47D cells, which can be clearly attributed to 
the transcriptional silencing (Figure 17A). CTCF overexpression and knockdown 
inversely regulate HOXA10 expression in T-47D, indicating a direct role of CTCF in 
HOXA10 silencing in T-47D (Figure 17B, C). Further, overexpression of CTCF in BT-
474 induce little silencing of HOXA10 compared to T-47D cells (Figure 17D, E). 
These results demonstrate that HOXA10 expression is negatively regulated by CTCF 
in breast cancer cells such as MCF-7 and T-47D, in which CTCF preferentially binds 
to the promoter region of HOXA10. In certain cell lines such as BT-474, CTCF does 
not affect HOXA10 expression because its binding is not preferred 
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Figure 17. CTCF modulate HOXA10 expression in T-47D cells but not in BT-474 (A) 
ChIP-PCR analysis of CTCF enrichment on HOXA10 promoter region (CBS1-A) in 
BT-474 and T-47D cells. (B) HOXA10 expression in control (pCDNA3) and CTCF 
over expressing (pCTCF) T-47D, as well as in un-treated (Cells). (C) HOXA10 
expression in CTCF knockdown (CTCF-KD) and control non-specific (Control-NS) 
T-47D cells. (D-E) Semi-quantitative RT-PCR of HOXA10 expression in CTCF 
overexpressing BT-474 and T-47D cells. The expression of genes in controls is set as 
100. n=3 and error bars are SE.  
 
6. CTCF and HOXA10 expression in breast tumor  
     CTCF mRNA levels in breast tumors are found to be higher as compared to its 
adjacent normal tissue while mRNA levels of HOXA10 are found lower in breast 
tumor as compared to adjacent normal in 14 samples (Figure 18). This shows that 
higher levels of CTCF in breast tumor contribute in tumorigenesis by HOXA10 
silencing. 
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Figure 18. Analysis of CTCF and HOXA10 mRNA levels in breast tumor. Semi-
quantitative RT-PCR analysis of CTCF and HOXA10 mRNA expression levels in 14 
breast tumor and their corresponding adjacent normal samples. 
 
7. CTCF differentially affect breast cancer cell proliferation 
     As CTCF is known to contribute in cancer cell survival
21
  and one of the reason 
is by transcriptional silencing of pro-apoptotic gene Bax in breast tumor.
13
 We wanted 
to explore how CTCF depletion affects the survival of MCF-7. We first designed a 
time course experiment to analyze the effect of CTCF knock down on proliferation of 
MCF-7 and MCF10A cells (Figure 19, Figure 20).  
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Figure 19. Experiment time line for CTCF knock down cells. 
 
Using MTT assay we observed that depletion of CTCF affect Cellular proliferation in 
MCF7 cells more than in MCF10A over the period of time. This indicates a possible 
higher dependency of cancer cell on CTCF than normal breast epithelia cells. 
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Figure 20. Effect of CTCF on cellular proliferation in MCF10A and MCF-7 cells. (A-
B) Cellular proliferation using MTT assay were monitored in a time course 
experiment using CTCF knock down (KD1, KD2 and KD3) and control (Non-specific 
(NS) and empty vector (pLKO.1)) MCF-7 and MCF10A cells. 
 
8. CTCF affects cancer cell survival and colony formation 
    In order to confirm that CTCF depletion is disadvantageous to the breast cancer 
cell lines, we developed cancer and normal cells co-culture system (MCF-7/MCF10A) 
and observed the effect of CTCF knock down on the two types of cells. In order to 
distinguish cancer cells (MCF-7) from normal breast epithelial cells (MCF10A), GFP 
expressing MCF-7 stable cell line clone MCF-7-GFP-H3 was generated (Figure 21A). 
CTCF mRNA levels of different GFP expressing MCF-7 clones were compared with 
wild type MCF-7 cells (Figure 21B). MCF-7-GFP-H3, which will be referred as 
MCF-7-GFP was used for co-culture. The two different cell lines can be distinguished 
using florescent microscopy (Figure 21C) in a co-culture system. Media was 
optimized to grow MCF-7-GFP/MCF10A co-culture to achieve similar growth rate 
(Figure 21D-E). 
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Figure 21. Optimization of MCF10A and MCF-7-GFP co culture. (A) Homogenous 
clone MCF-7-GFP-H3, expressing stably transfected GFP using pEGFP-N1 empty 
vector. (B) mRNA expression of CTCF in MCF-7 and GFP expressing MCF-7 clones. 
(C) MCF-7-GFP/MCF10A co-culture in optimized experimental media. (D-E) 
Growth rate of MCF-7-GFP and MCF10A cells in their standard media and in 
optimized experimental media. 
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CTCF knocked down (MCF-7-GFP) cancer and normal breast epithelial cells 
(MCF10A) were used to grow in co-culture with selection marker. It was observed 
that MCF-7-GFP cells failed to maintained their colonies and aggregates between day 
4 and day 6 (Figure 19) in CTCF knock down conditions. We also failed to prepare 
CTCF knock down stable cell line. This observation confirms that consistent 
depletion of CTCF over the period of time affect cancer cell survival and colony 
formation. 
 
 
 
Figure 22. Growth of MCF-7/MCF10A co-culture in CTCF depleted conditions. (A) 
Florescent microscopy of MCF-7-GFP/MCF10A co-culture in control NS and in 
CTCF knock down conditions. (B-C) Zoom in images of square boxes indicated in d-
e and i-j.  
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9. CTCF negatively regulate tumor suppressor TP53 and HOXC8 
expression in MCF-7 
      Next we investigated that whether CTCF affect cancer cell survival through p53 
pathway or not? We observed that mRNA levels of TP53 and its downstream 
members of cascade, p21 and Bax were up-regulated in CTCF-knock down cells, 
(Figure 23A) which can induce cell cycle arrest and apoptosis in cancer cells. Breast 
cancer tumor suppressor HOXC8 is also found to be upregulated in CTCF knock 
down MCF-7cells.  
 
 
 
Figure 23. CTCF regulation of TP53 and HOXC8 in breast cancer cell line MCF-7. 
(A) mRNA expression of TP53, p21, Bax and HOXC8 in CTCF knock down (KD1 
and KD2) and control cells (NS, pLKO.1 and cells). (B-C) ChIP-PCR analysis to 
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observe histone modification (H3K4me3 and H3K27me3) on promoter region of 
TP53 and HOXC8 in Control NS and CTCF knock down MCF-7 cells.  
 
TP53 and HOXC8 harbors a CTCF binding site near their promoter region,
45
 it is 
expected that CTCF might negatively regulates these two genes in the same was as it 
does in HOXA10.
13
 To establish a direct transcriptional role of CTCF in regulation of 
TP53 and HOXC8, we performed ChIP analysis to observe histone modifications on 
promoter region of TP53 and HOXC8 using our control non specific (Control-NS) 
and CTCF knock down MCF-7cells (CTCF-KD) (Figure 23B-C). We found that 
enrichment of CTCF near the promoter region of TP53 and HOXC8 is marked with 
repressive histone marks H3K27me3 and its depletion activate the promoter region 
with recruitment of active histone marks H3K4me3. Taken together we concluded that 
CTCF induce transcriptional silencing to TP53 and HOXC8 by binding to their 
promoter region. CTCF depletion activate promoter region of TP53 and HOXC8 and 
upregulate their transcription and transcription of their downstream genes. Our ICC 
data confirms that in control and CTCF knock down MCF-7 cells p53 nuclear 
expression is related to CTCF depleted nuclei only. (Figure 24) 
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Figure 24. CTCF and p53 localization in MCF-7 cells. (A) Fluorescent microscopy 
images showing expression of p53 (green) and CTCF (red), DAPI (blue) and merge in 
control non-specific a-d and CTCF knock down e-h cells. i-l and m-p are zoom in 
images from the area marked in square boxes in d and h respectively. Scale bar = 20μ
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m. 
10. Nuclear p53 co-localize with HOXA10 in breast cancer cell lines 
      HOXA10 is known to activate p53,
47
 and we observed negative regulation of 
both HOXA10 and p53 in MCF-7, next we ask whether HOXA10 and p53 expression 
is related to each other or not? To find the answer we did ICC experiment to see p53 
and HOXA10 expression in control and CTCF knock down MCF-7 cells. We found 
that nuclear expression of p53 in CTCF knock down cells is strongly related to the 
nuclear expression of HOXA10 (Figure 25). The observed co-localization of 
HOXA10 and p53 established a possible link of HOXA10 with p53 nuclear 
localization and activation. We concluded that upregulation and nuclear localization 
of HOXA10 in CTCF knock down MCF-7 cells also activate or stabilize p53 possibly 
by nuclear import or co-localization. 
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Figure 25. HOXA10 and p53 localization in MCF-7 cells. (A) Confocal microscopic 
images showing p53, HOXA10, DAPI and Merge of control non-specific (Control-NS) 
a-d and CTCF knock down (CTCF-KD) e-h MCF-7 cells. 
 
HOXA10 and p53 co-localization was also observed in HOXA10 expressing BT-474 
cells but not in T-47D cells in which the HOXA10 is silenced by CTCF.
13
 (Figure 26) 
 
 
 
Figure 26. HOXA10 and p53 localization in BT-474 and T-47D cells. (A) Confocal 
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microscopy showing p53, HOXA10, DAPI and Merge of BT-474 a-d and T-47D e-h 
cells. i-l zoom in images of area highlighted in square box in d. 
 
11. CTCF knock down affects cell cycle progression in MCF-7 
      Since CTCF depletion activates p53 cascade, therefore we next analyzed 
population distribution of different phases of cell cycle in control and CTCF knock 
down cells. Cell cycle analysis using FACS showed, CTCF knock down cells have 
increased population in G1 and decreased population of S phase as compared to the 
control non-specific cells (Figure 27). This observation indicated  G1/S cell cycle 
arrest in CTCF knock down cells possibly as a result of upregulation of p21 
(Figure23A). 
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Figure 27. Fluorescence-activated cell sorting (FACS) analysis of cell cycle using PI. 
(A) Cell cycle distribution of control non-specific (Control-NS) and CTCF knock 
down (CTCF-KD) MCF-7 cells. (B) Population distribution of cell cycle phases from 
figure A. 
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12. Depleted CTCF levels in MCF-7 induce apoptosis 
      One possible outcome of activation of p53 cascade in CTCF knock down cells 
is the induction of apoptosis. To confirm that we used Annexin V and PI staining to 
observe early and late apoptotic cells using control and CTCF knock down cells. We 
found increased number of apoptotic cells in CTCF knock down conditions.   
 
 
 
Figure 28. Fluorescence-activated cell sorting (FACS) analysis of apoptosis. 
(A)  Representative scatter plots showing the distribution of annexin V and PI 
staining for control non-specific (Control-NS) and CTCF knock down (CTCF-KD) 
MCF-7 cells. Cells are classified as “viable” (bottom left), “early apoptotic” (bottom 
54 
 
right), “apoptotic” (top right), or “necrotic” (top left and right). (B) Quantitative 
analysis of the percentage of apoptotic by FACS analysis.  
 
13. CTCF influence autophagy in MCF-7 cells 
      To analyze the effect of CTCF on autophagy, mRNA levels of two important 
autophagy markers p62 (SQSTM1) and ATG13 were measure and found to be up-
regulated in CTCF over expressing (pCTCF) MCF-7 cells (Figure 29A). To explore 
further we used Lysotracker staining of lysosomes in control and CTCF knock down 
cells. It was observed that lysosome number decreased sharply in CTCF knock down 
MCF-7 cells (Figure 29B). This indicates a possibility that depletion of CTCF might 
block autophagy which results in reduced lysosome numbers.  
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Figure 29: Analysis of autophagy. (A) mRNA levels of autophagy markers p62 and 
ATG13 in control (pCDNA3), CTCF over expressing (pCTCF) and un treated MCF-7 
cells (B) Fluorescent microscopy images of MCF-7 control non-specific (Control-NS) 
and CTCF knock down (CTCF-KD) cells stained with lysotracker and Hoechst 34580 
to show lysosomes and nucleus in live cells. 
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14. PCR array analysis of CTCF knock down MCF-7 cells 
Using Human Breast Cancer RT² Profiler™ PCR Array, expression of 84 key genes 
commonly involved in the dysregulation of signal transduction and other normal 
biological processes during breast carcinogenesis were analyzed in CTCF knock 
down (CTCF-KD) and control non-specific (CTCF-NS) cells.This array includes 
genes involved in tumor classification, signal transduction, and other commonly 
affected pathways such as angiogenesis, adhesion, proteolysis, cell cycle, and 
apoptosis. It was revealed that several breast cancer markers as well as genes involved 
in metastasis are suppressed after CTCF knock down. The downregulation of these 
cancer contributors, affect the overall survival of MCF-7 cells by changing the global 
transcriptome in favour of reduced progression and tumorigenesis.  
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Table 5. Functional gene grouping for PCR array analysis 
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Figure 30. Human breast cancer PCR array profile. (A) Heat map showing change in 
expression of mRNA levels in CTCF knock down vs control cells. (B) Plate labeling 
with gene annotations and fold change of expression.  
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  15. Significance of HOXA10 in activation of p53 in breast cancer 
patients 
      HOXA10 is known to interact directly with TP53 (Figure 31), this interaction 
will activate p53 cascade to induce cell cycle arrest and apoptosis provided that a 
functional p53 is available in the system. In order to investigate that HOXA10 
expression is significantly associated with breast cancer with reference to p53, we 
used Kaplan Meier survival analysis of breast cancer patients. It was revealed that  
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Figure 31. STRING - Known and Predicted Protein-Protein Interactions of HOXA10 
with p53. 
 
higher expression of HOXA10 does not affect the overall survival (OS) and distant 
metastasis free survival (DMSF) of breast cancer patients (Figure 32A, B). On the 
other hand patients with higher HOXA10 have significantly higher probability of OS 
and DMFS if they carry a wild type copy of p53 (Figure 32 C, D). We concluded from 
this observation that HOXA10 asserts its tumor suppressor role via activation of p53 
in breast cancer patients.  
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Figure 32: Kaplan Meier survival analysis of breast cancer patients. (A-B) Overall 
survival and distant metastasis free survival of breast cancer patients with high and 
low expression of HOXA10 in all patients. (C-D) Overall survival and distant 
metastasis free survival of breast cancer patients with high and low expression of 
HOXA10 in patients with wild type p53. 
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IV. DISCUSSION 
     
In this study, we provide experimental evidence to explain how CTCF contribute 
in breast cancer tumorigenesis. We identified HOXA10 as one of the directly regulated 
tumor suppressor gene by CTCF at transcriptional level in breast cancer cell lines. 
Our dual luciferase reporter assay data defined novel promoter region of HOXA10, 
and moreover, ChIP analysis established the inverse relationship between CTCF 
enrichment on the promoter region and transcriptional activity of HOXA10 gene. 
Depletion of CTCF was marked with decreased repressive histone marks H3K27me3 
on HOXA10 promoter region in MCF-7 cells and differential CTCF binding inversely 
related to the expression levels of HOXA10 in BT-474 and T-47D cells. HOXA10 has 
three exons and two transcript variants, transcript variant 1 (originated from exon 2 
and exon 3) and 2 (originated from exon 1 and exon 3). The functional protein is 
encoded by transcript variant 1. Our work provide evidence that HOXA10 lacks 
promoter activity immediately upstream of its protein coding exon 2, instead the 
HOXA10 locus showed promoter activity 5.3-6.1 kb upstream of its start codon within 
the non-coding exon 1. Chromatin interaction analysis with paired end tag sequencing 
(ChIA-PET) have revealed that extensive RNA POL2 based chromatin interaction 
exists between 3’ of exon 1 and 5’ of exon 2 region of genomic DNA on HOXA10 
locus.
48
 The presence of RNA POL2 on HOXA10 promoter region creates active 
chromatin confirmation of HOXA10 locus with promoter region that lies in the three 
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dimensional (3D) neighborhood of protein coding exon 2 of HOXA10. CTCF may 
oppose this active state in MCF-7 cells by not allowing the recruitment RNA POL2.  
In most cases the CTCF binding is regulated by CpG methylation,
43
 therefore, it is 
highly likely that methylation status of CpGs present the promoter region of HOXA10 
in breast cancer cell lines defines the CTCF enrichment and HOXA10 expression. 
HOXA10 expression in T-47D cells can be modulated with CTCF, while HOXA10 
expression seems to be independent of CTCF in BT-474 cells which have little 
enrichment of CTCF on HOXA10 promoter (Figure 17). This effect appeared possibly 
due to differential methylation pattern, which make CTCF binding on HOXA10 
promoter to be more favorable in T-47D than in BT-474 cells.  
We identified a CTCF core motif, based on previously reported consensus sequence,
46
 
within HOXA10 promoter region. It was demonstrated previously that CTCF protein 
interacts with POLR2A,
49
 which is enough to interplay with transcription machinery. 
Using in vitro mutation assay we found that CTCF core motif within the HOXA10 
promoter region is flanked with an important promoter element (Figure 15). This 
promoter element is no longer available to take part in transcriptional activity as long 
as it is occupied with CTCF. The presence of CTCF near the promoter region of 
HOXA10 induces silencing effect not only by interfering transcriptional machinery 
but also by maintaining repressive chromatin state. One possibility is that CTCF-
POLR2A interaction can induce RNA poll II stalling to reduce transcription of 
HOXA10. CTCF based transcriptional silencing is not limited to HOXA10 in this 
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study but we also found that HOXC8 and TP53 are also regulated by CTCF in the 
same way.  
In BRCA mutant breast cancer patients, several HOX genes including HOXA10 are 
frequently silenced by hypermethylation.
37
 HOXA10 expression regulates p53 in 
breast cancer cells
34
 and its reduced expression contributes towards invasion and 
metastasis.
50
 Higher levels of CTCF gives survival advantage to breast cancer cells by 
conferring resistance towards apoptosis as a result of epigenetic silencing of Bax
13, 21
 
as well as tumor suppressors HOXA10,HOXC8 and TP53 in the same way. In this 
study we present a novel silencing mechanism of HOXA10 in breast cancer cell lines 
by CTCF occupancy on the core promoter region of HOXA10.
51
 This is different from 
general mechanism of methylation-dependent gene silencing which can inactivate the 
promoter region of HOXA10 for all transcription factors. 
Inverse transcriptional regulation of target genes by CTCF, harboring a CTCF binding 
site near promoter region, works similarly and can be rationalized as in case of Bax 
and HOXA10. The CTCF presence near promoter region not only maintains inactive 
local chromatin state but also interferes with transcriptional machinery to induce 
silencing. Identification of other molecules which can be negatively regulated by 
CTCF will help to understand how a single factor CTCF affects the overall 
transcriptome of breast cancer cells. 
CTCF mediated silencing of tumor suppressor like HOXA10, HOXC8 and TP53 
downplay the function of a key anticancer pathway in breast cancer cells. Depletion 
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of CTCF in breast cancer cells activates p53 cascade directly or via HOXA10 and 
induce cell cycle arrest as well as apoptosis. HOXA10 upregulation increase nuclear 
HOXA10 which co-localize with p53 and might involve its nuclear import or 
stabilization. Since MCF-7 carries a wild type p53 therefore a cancer phenotype of 
MCF-7 is strongly related to either, transcriptional downregulation of p53 gene or 
inactivation of p53 protein by MDM2, the main ubiquitin ligase of p53. In the context 
of MCF-7, CTCF can serve this purpose by transcription downregulation of p53 as 
well as HOXA10. As a result of cellular stress, p53 is stabilized and rapidly 
accumulates in the nucleus to serve its function.
52
 We showed that nuclear localization 
of p53 in MCF-7 cells is inhibited by the CTCF and associated with nuclear HOXA10. 
Nuclear HOXA10 might contribute in p53 nuclear localization to trigger cell’s 
internal defense mechanism in MCF-7 cells. Identification and restoration of tumor 
suppressors which are inhibited by CTCF can be achieved by targeted genome 
engineering of CTCF binding sites. Reactivation of cellular resources to cope 
oncogenic transformation could provide an additional choice of treatment in the 
ongoing struggle against cancer. 
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V. CONCLUSION 
   CTCF inversely regulates HOXA10, HOXC8 and TP53 in breast cancer cells. 
HOXA10 promoter was identified 5.3-6.1 kb upstream of the protein coding region 
(Figure 33). CTCF binding to the promoter region maintains inactive local chromatin 
state at HOXA10 promoter and induce transcriptional silencing. In addition to that 
CTCF presence on HOXA10 promoter interferes with transcriptional machinery by 
flanking important promoter element. Depletion of CTCF in breast cancer cells results 
in activation of HOXA10 promoter region and increased transcription.
13
  
 
 
Figure 33. Mechanism of HOXA10 regulation.  
 
CTCF confers transcriptional silencing of p53 cascade directly or through HOXA10 
to contribute in breast cancer tumorigenesis. CTCF depletion activates TP53 and 
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increased nuclear HOXA10 which co-localize with p53. The activation of p53 induces 
cell cycle arrest and apoptosis and suppresses cancer cell progression and survival. 
 
 
 
Figure 34. CTCF based inactivation of p53 cascade. 
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ABSTRACT IN KOREAN 
 
유방암 발생 및 진행에 있어서 CTCF의 기능과  
HOX 유전자의 조절자로서의 역할 규명  
 
<지도교수 김명희> 
 
연세대학교 대학원 의과학과 
 
무하마드 무스타파 
 
 
CTCF (또는 CCCTC-binding factor)는 11개의 징크핑거(zinc finger) 도메인을 
가지고 있는 다기능 단백질로서 유전자 좌위 특이적으로 전사의 촉진 또는 
억제, 인헨서 블로킹 등의 기능을 수행한다. 다양한 암 종에서 CTCF의 체세
포 돌연변이가 발견된다는 점과 CTCF가 세포의 성장, 분화, 세포사멸 등에 
관여한다는 점은 암의 진행에 있어서 CTCF가 중요한 역할을 할 것임을 시사
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한다. HOX 유전자는 배아 발생 중 형태형성에 있어서 중요한 역할을 담당할 
뿐 아니라 성인 세포 내에서도 다양한 세포 내 기능을 조절한다. 따라서 
HOX 유전자의 비정상적인 발현이 유방암을 포함한 다양한 암 종에서 많이 
발견되고 있다. 본 연구에서는 CTCF가 직접적으로 또는 HOX 유전자의 조절
을 통해서 유방암세포의 성장에 미치는 영향을 분석하였다.   
CTCF의 과발현(gain of function) 또는 기능억제(loss of function) 연구를 통해서 
HOX 유전자 발현에의 영향과 유방암 세포성장에의 영향을 살펴보았다. 
HOX 유전자 중에서 HOXA4, HOXC8, HOXA10이 CTCF에 의해 조절되는 양상
을 보였다. 특히 HOXA10은 p53 활성에 영향을 주고 암의 발생과정에 대응
하는 역할을 함이 알려져서 새로운 암 억제 유전자로 제시된 바 있다. 여러 
암 종에서 암의 발생과 HOXA10의 비활성화와의 관련성을 보여주고 있지만 
HOXA10의 조절기전에 대해서는 잘 알려져 있지 않다. 본 연구결과에서는 
HOXA10의 프로모터로 예측되는 부위가 전사시작부위로부터 앞쪽으로 5.3-
6.1 kb 떨어져 있는 지점에 위치함을 밝혔고 프로모터 기능이 CTCF에 의해 
억제됨을 보여주었다. 히스톤 변형패턴 분석을 통해 HOXA10 좌위에서의 
CTCF의 존재는 유전자 활성 마커인 H3K4me3의 감소와 유전자 억제 마커인 
H3K27me3의 증가를 유도함을 확인하였다. 또한 In silico 분석법과 in vitro 돌
연변이 분석 검정을 통해 HOXA10의 중요 프로모터 부위에 CTCF core motif
가 중복되어 위치함을 확인하였다. 이상의 결과들로 미루어 볼 때 HOXA10
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의 중요 프로모터 부위에 CTCF가 결합함으로써 크로마틴의 환경을 비활성
화 시키고 전사인자들의 접근을 방해함으로써 HOXA10 발현을 억제할 것으
로 보인다. 유방암세포에서 CTCF에 의한 HOXA10의 후생적 침묵(epigenetic 
silencing)은 세포주기가 정지됨을 막고 세포사멸을 감소시키고 전이를 촉진
시키는 등 종양형성을 진행시키는 요인으로 작용할 것이다.  
CTCF의 발현을 억제시킨 경우 세포성장 및 증식의 감소 효과가 정상 유방상
피세포주인 MCF10A에서보다 유방암세포주인 MCF-7에서 더 크게 나타났다. 
유방암세포에서의 CTCF 발현저해는 직간접적으로 p53 신호 캐스캐이드를 
조절할 것으로 보인다. p53 프로모터 부위에의 CTCF 결합은 H3K27me3의 증
가와 H3K4me3의 감소를 동반함을 확인하였다. CTCF의 발현을 저해하면 p53
의 활성화와 함께 p21의 발현이 증가하여 G1/S check point에서의 세포주기 
정지, Bax 유전자의 발현에 의한 세포사멸의 증가가 유도된다. MCF-7에서 
p53이 핵 내에 존재하는 위치는 CTCF의 발현억제와 연관이 있는데 본 연구
결과에서 CTCF 발현억제하에서 p53 신호 캐스캐이드가 활성화됨을 보여주
었으며 CTCF에 의한 HOXA10의 전사 억제 효과 역시 p53을 활성화시키는 
기전으로 작용함을 확인하였다. 유방암세포주에서 HOXA10은 p53과 발현하
는 위치가 같게 나타나는데 HOXA10의 발현저해는 핵내 p53의 감소를 초래
하였다. 오토파지 신호경로의 주요 인자인 ATG13, SQSTM1 (P62), LC3-II와 
리소좀의 갯수도 CTCF 발현양과 양의 상관관계가 있음을 확인하였다.  
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이상의 결과들은 CTCF가 직접적으로, 또는 HOXA10을 통해서 p53의 전사억
제를 유도하며 이는 유방암세포의 성장 및 발달에 관여함을 보여준다.    
 
------------------------------------------------------------------------------------------------------- 
핵심되는 말: 유방암, CTCF, HOXA10, p53  
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